nogrЭкспериментальная и клиническая гастроэнтерологияExperimental and Clinical Gastroenterology1682-8658«Global Media Technologies»10.31146/1682-8658-ecg-220-12-164-182nogr-2663Research ArticleОБЗОРREVIEWСовременные представления об этиологии и патогенезе воспалительных заболеваний кишечника (Часть 2): роль микробиома и нутритивных факторовCurrent understanding of the aetiology and pathogenesis of inflammatory bowel diseases (Part 2): the role of the microbiome and nutritional factorshttps://orcid.org/0000-0001-7308-7280ХавкинА. И.KhavkinA. I.khavkin@nikid.ruhttps://orcid.org/0000-0001-8364-6066НиколайчукК. М.NikolaychukK. M.noemail@neicon.ruhttps://orcid.org/0000-0003-3606-4068ШрайнерЕ. В.ShraynerE. V.noemail@neicon.ruhttps://orcid.org/0009-0009-7816-5562ШаймардановаД. Р.ShaimardanovaD. R.noemail@neicon.ruhttps://orcid.org/0009-0002-9228-2350ВеременкоА. С.VeremenkoA. S.noemail@neicon.ruhttps://orcid.org/0009-0002-7317-6077ЛевченкоИ. Д.LevchenkoI. D.noemail@neicon.ruhttps://orcid.org/0009-0004-1880-9585ПлатоноваП. Я.PlatonovaP. Ya.noemail@neicon.ruhttps://orcid.org/0009-0008-7479-8277НовиковаМ. Ф.NovikovaM. F.noemail@neicon.ruhttps://orcid.org/0000-0002-6271-5218ДудуричВ. В.DudurichV. V.noemail@neicon.ruНаучно-исследовательский клинический институт детства Министерства здравоохранения Московской области; Белгородский государственный исследовательский университет Министерства науки и высшего образования Российской ФедерацииРоссияResearch Clinical Institute of Childhood, Ministry of Health of the Moscow Region; Belgorod State Research UniversityRussian FederationНовосибирский государственный университетРоссияNovosibirsk State UniversityRussian FederationНовосибирский государственный университет; Институт химической биологии и фундаментальной медицины СО РАНРоссияNovosibirsk State University; Institute of Chemical Biology and Fundamental Medicine of the SB RASRussian FederationФедеральное государственное автономное образовательное учреждение высшего образования «Национальный исследовательский университет ИТМО»; «Сербалаб» генетическая лабораторияРоссияITMO National Research University; “Сerbalab” laboratoryRussian Federation202318122023012164182Copyright © Хавкин А.И., Николайчук К.М., Шрайнер Е.В., Шаймарданова Д.Р., Веременко А.С., Левченко И.Д., Платонова П.Я., Новикова М.Ф., Дудурич В.В., 20232023Хавкин А.И., Николайчук К.М., Шрайнер Е.В., Шаймарданова Д.Р., Веременко А.С., Левченко И.Д., Платонова П.Я., Новикова М.Ф., Дудурич В.В.Khavkin A.I., Nikolaychuk K.M., Shrayner E.V., Shaimardanova D.R., Veremenko A.S., Levchenko I.D., Platonova P.Y., Novikova M.F., Dudurich V.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.nogr.org/jour/article/view/2663

В рамках работы проведен обзор современных данных о структуре микробиоты и её взаимодействии с хозяином, а также оценено влияние микробного сообщества на иммунную систему и развитие хронического воспаления в желудочно-кишечном тракте. В обзоре представлены современные даные о влияние диеты на ход и терапию ВЗК. Изучение роли микробиоты и диеты в патогенезе ВЗК показало, что микробный дисбиоз и вирус Эпштейна-Барр могут усугублять течение ВЗК. Определённые продукты ухудшают симптомы, в то время как моносахаридная диета способствует ремиссии. Результаты подчёркивают важность индивидуального подхода к питанию для улучшения лечения ВЗК.

This work reviews current data on the structure of the microbiota and its interaction with the host, and assesses the impact of the microbial community on the immune system and the development of chronic inflammation in the gastrointestinal tract. This review presents current evidence on the influence of diet on the course and therapy of GI tract inflammation. Studies on the role of microbiota and diet in the pathogenesis of ICD have shown that microbial dysbiosis and Epstein-Barr virus can exacerbate the course of ICD. Certain foods worsen symptoms, while a monosaccharide diet favours remission. The results emphasise the importance of an individualised nutritional approach to improve the treatment of IBS.

воспалительные заболевания кишечникаболезнь Кронаязвенный колитпатогенеземикробиотапитание и диета при ВЗКInflammatory bowel diseaseCrohn’s diseaseulcerative colitispathogenesismicrobiotanutrition and diet in IBDReferencesSelvamani S., Mehta V., Ali El Enshasy H., Thevarajoo S., El Adawi H., Zeini I., Pham K., Varzakas T., Abomoelak B. Efficacy of Probiotics-Based Interventions as Therapy for Inflammatory Bowel Disease: A Recent Update. Saudi J Biol Sci. 2022 May;29(5):3546-3567. doi: 10.1016/j.sjbs.2022.02.044.Selvamani S., Mehta V., Ali El Enshasy H., Thevarajoo S., El Adawi H., Zeini I., Pham K., Varzakas T., Abomoelak B. Efficacy of Probiotics-Based Interventions as Therapy for Inflammatory Bowel Disease: A Recent Update. Saudi J Biol Sci. 2022 May;29(5):3546-3567. doi: 10.1016/j.sjbs.2022.02.044.Haneishi Y., Furuya Y., Hasegawa M., Picarelli A., Rossi M., Miyamoto J. Inflammatory Bowel Diseases and Gut Microbiota.Int J Mol Sci. 2023 Feb 14;24(4):3817. doi: 10.3390/ijms24043817.Haneishi Y., Furuya Y., Hasegawa M., Picarelli A., Rossi M., Miyamoto J. Inflammatory Bowel Diseases and Gut Microbiota.Int J Mol Sci. 2023 Feb 14;24(4):3817. doi: 10.3390/ijms24043817.Jie Wang, Puxuan Zhang, Shujie Chen, Huimin Duan, Liwei Xie. Microbiota and Gut Health: Promising Pro-spects for Clinical Trials from Bench to Bedside. Advanced Gut & Microbiome Research. 2022: Article ID 2290052. doi: 10.1155/2022/2290052.Jie Wang, Puxuan Zhang, Shujie Chen, Huimin Duan, Liwei Xie. Microbiota and Gut Health: Promising Pro-spects for Clinical Trials from Bench to Bedside. Advanced Gut & Microbiome Research. 2022: Article ID 2290052. doi: 10.1155/2022/2290052.Aldars-García L., Chaparro M., Gisbert J. P. Systematic Review: The Gut Microbiome and Its Potential Clinical Application in Inflammatory Bowel Disease. Microorganisms. 2021 Apr 30;9(5):977. doi: 10.3390/microorganisms9050977.Aldars-García L., Chaparro M., Gisbert J. P. Systematic Review: The Gut Microbiome and Its Potential Clinical Application in Inflammatory Bowel Disease. Microorganisms. 2021 Apr 30;9(5):977. doi: 10.3390/microorganisms9050977.Elzayat H., Mesto G., Al-Marzooq F. Unraveling the Impact of Gut and Oral Microbiome on Gut Health in Inflammatory Bowel Diseases. Nutrients. 2023 Jul 29;15(15):3377. doi: 10.3390/nu15153377.Elzayat H., Mesto G., Al-Marzooq F. Unraveling the Impact of Gut and Oral Microbiome on Gut Health in Inflammatory Bowel Diseases. Nutrients. 2023 Jul 29;15(15):3377. doi: 10.3390/nu15153377.Senapati T., Kothidar A., Banerjee S. K., DAS B. Insights into the gastrointestinal tract microbiomes of Indian population. J Biosci. 2019 Oct;44(5):113. PMID: 31719222.Senapati T., Kothidar A., Banerjee S. K., DAS B. Insights into the gastrointestinal tract microbiomes of Indian population. J Biosci. 2019 Oct;44(5):113. PMID: 31719222.Pittayanon R., Lau J. T., Leontiadis G. I., Tse F., Yuan Y., Surette M., Moayyedi P. Differences in Gut Microbiota in Patients With vs Without Inflammatory Bowel Diseases: A Systematic Review. Gastroenterology. 2020 Mar;158(4):930-946.e1. doi: 10.1053/j.gastro.2019.11.294.Pittayanon R., Lau J. T., Leontiadis G. I., Tse F., Yuan Y., Surette M., Moayyedi P. Differences in Gut Microbiota in Patients With vs Without Inflammatory Bowel Diseases: A Systematic Review. Gastroenterology. 2020 Mar;158(4):930-946.e1. doi: 10.1053/j.gastro.2019.11.294.Quévrain E., Maubert M. A., Michon C. et al. Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn’s disease. Gut. 2016 Mar;65(3):415-425. doi: 10.1136/gutjnl-2014-307649.Quévrain E., Maubert M. A., Michon C. et al. Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn’s disease. Gut. 2016 Mar;65(3):415-425. doi: 10.1136/gutjnl-2014-307649.Parada Venegas D., De la Fuente M. K., Landskron G., González M. J., Quera R., Dijkstra G., Harmsen H. J.M., Faber K. N., Hermoso M. A. Corrigendum: Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases. Front Immunol. 2019 Jun 28;10:1486. doi: 10.3389/fimmu.2019.01486.Parada Venegas D., De la Fuente M. K., Landskron G., González M. J., Quera R., Dijkstra G., Harmsen H. J.M., Faber K. N., Hermoso M. A. Corrigendum: Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases. Front Immunol. 2019 Jun 28;10:1486. doi: 10.3389/fimmu.2019.01486.Lal S., Kandiyal B., Ahuja V., Takeda K., Das B. Gut microbiome dysbiosis in inflammatory bowel disease. Prog Mol Biol Transl Sci. 2022;192(1):179-204. doi: 10.1016/bs.pmbts.2022.09.003.Lal S., Kandiyal B., Ahuja V., Takeda K., Das B. Gut microbiome dysbiosis in inflammatory bowel disease. Prog Mol Biol Transl Sci. 2022;192(1):179-204. doi: 10.1016/bs.pmbts.2022.09.003.Pareek S., Kurakawa T., Das B. et al.Comparison of Japanese and Indian intestinal microbiota shows diet-dependent interaction between bacteria and fungi. NPJ Biofilms Microbiomes. 2019 Dec 20;5(1):37. doi: 10.1038/s41522-019-0110-9.Pareek S., Kurakawa T., Das B. et al.Comparison of Japanese and Indian intestinal microbiota shows diet-dependent interaction between bacteria and fungi. NPJ Biofilms Microbiomes. 2019 Dec 20;5(1):37. doi: 10.1038/s41522-019-0110-9.Li X.V., Leonardi I., Iliev ID. Gut Mycobiota in Immunity and Inflammatory Disease. Immunity. 2019 Jun 18;50(6):1365-1379. doi: 10.1016/j.immuni.2019.05.023.Li X.V., Leonardi I., Iliev ID. Gut Mycobiota in Immunity and Inflammatory Disease. Immunity. 2019 Jun 18;50(6):1365-1379. doi: 10.1016/j.immuni.2019.05.023.Limon J.J., Tang J., Li D. et al. Malassezia Is Associated with Crohn’s Disease and Exacerbates Colitis in Mouse Models. Cell Host Microbe. 2019 Mar 13;25(3):377-388.e6. doi: 10.1016/j.chom.2019.01.007.Limon J.J., Tang J., Li D. et al. Malassezia Is Associated with Crohn’s Disease and Exacerbates Colitis in Mouse Models. Cell Host Microbe. 2019 Mar 13;25(3):377-388.e6. doi: 10.1016/j.chom.2019.01.007.Naglik J.R., Gaffen S. L., Hube B. Candidalysin: discovery and function in Candida albicans infections. Curr Opin Microbiol. 2019 Dec;52:100-109. doi: 10.1016/j.mib.2019.06.002.Naglik J.R., Gaffen S. L., Hube B. Candidalysin: discovery and function in Candida albicans infections. Curr Opin Microbiol. 2019 Dec;52:100-109. doi: 10.1016/j.mib.2019.06.002.Sokol H., Leducq V., Aschard H., Pham H. P. et al. Fungal microbiota dysbiosis in IBD. Gut. 2017 Jun;66(6):1039-1048. doi: 10.1136/gutjnl-2015-310746.Sokol H., Leducq V., Aschard H., Pham H. P. et al. Fungal microbiota dysbiosis in IBD. Gut. 2017 Jun;66(6):1039-1048. doi: 10.1136/gutjnl-2015-310746.Qiu X., Ma J., Jiao C., Mao X., Zhao X., Lu M., Wang K., Zhang H. Alterations in the mucosa-associated fungal microbiota in patients with ulcerative colitis. Oncotarget. 2017 Nov 20;8(64):107577-107588. doi: 10.18632/oncotarget.22534.Qiu X., Ma J., Jiao C., Mao X., Zhao X., Lu M., Wang K., Zhang H. Alterations in the mucosa-associated fungal microbiota in patients with ulcerative colitis. Oncotarget. 2017 Nov 20;8(64):107577-107588. doi: 10.18632/oncotarget.22534.Li Q., Wang C., Tang C., He Q., Li N., Li J. Dysbiosis of gut fungal microbiota is associated with mucosal inflammation in Crohn’s disease. J Clin Gastroenterol. 2014 Jul;48(6):513-23. doi: 10.1097/MCG.0000000000000035.Li Q., Wang C., Tang C., He Q., Li N., Li J. Dysbiosis of gut fungal microbiota is associated with mucosal inflammation in Crohn’s disease. J Clin Gastroenterol. 2014 Jul;48(6):513-23. doi: 10.1097/MCG.0000000000000035.Hoarau G., Mukherjee P. K., Gower-Rousseau C. et al. Bacteriome and Mycobiome Interactions Underscore Microbial Dysbiosis in Familial Crohn’s Disease. mBio. 2016 Sep 20;7(5): e01250-16. doi: 10.1128/mBio.01250-16.Hoarau G., Mukherjee P. K., Gower-Rousseau C. et al. Bacteriome and Mycobiome Interactions Underscore Microbial Dysbiosis in Familial Crohn’s Disease. mBio. 2016 Sep 20;7(5): e01250-16. doi: 10.1128/mBio.01250-16.Imai T., Inoue R., Kawada Y., Morita Y., Inatomi O., Nishida A., Bamba S., Kawahara M., Andoh A. Characterization of fungal dysbiosis in Japanese patients with inflammatory bowel disease. J Gastroenterol. 2019 Feb;54(2):149-159. doi: 10.1007/s00535-018-1530-7.Imai T., Inoue R., Kawada Y., Morita Y., Inatomi O., Nishida A., Bamba S., Kawahara M., Andoh A. Characterization of fungal dysbiosis in Japanese patients with inflammatory bowel disease. J Gastroenterol. 2019 Feb;54(2):149-159. doi: 10.1007/s00535-018-1530-7.Liguori G., Lamas B., Richard M. L. et al. Fungal Dysbiosis in Mucosa-associated Microbiota of Crohn’s Disease Patients. J Crohns Colitis. 2016 Mar;10(3):296-305. doi: 10.1093/ecco-jcc/jjv209.Liguori G., Lamas B., Richard M. L. et al. Fungal Dysbiosis in Mucosa-associated Microbiota of Crohn’s Disease Patients. J Crohns Colitis. 2016 Mar;10(3):296-305. doi: 10.1093/ecco-jcc/jjv209.Shkoporov A.N., Clooney A. G., Sutton T. D.S. et al. The Human Gut Virome Is Highly Diverse, Stable, and Individual Specific. Cell Host Microbe. 2019 Oct 9;26(4):527-541.e5. doi: 10.1016/j.chom.2019.09.009.Shkoporov A.N., Clooney A. G., Sutton T. D.S. et al. The Human Gut Virome Is Highly Diverse, Stable, and Individual Specific. Cell Host Microbe. 2019 Oct 9;26(4):527-541.e5. doi: 10.1016/j.chom.2019.09.009.Wang W., Jovel J., Halloran B. et al. Metagenomic analysis of microbiome in colon tissue from subjects with inflammatory bowel diseases reveals interplay of viruses and bacteria. Inflamm Bowel Dis. 2015 Jun;21(6):1419-27. doi: 10.1097/MIB.0000000000000344.Wang W., Jovel J., Halloran B. et al. Metagenomic analysis of microbiome in colon tissue from subjects with inflammatory bowel diseases reveals interplay of viruses and bacteria. Inflamm Bowel Dis. 2015 Jun;21(6):1419-27. doi: 10.1097/MIB.0000000000000344.Norman J.M., Handley S. A., Baldridge M. T. et al. Disease-specific alterations in the enteric virome in inflammatory bowel disease. Cell. 2015 Jan 29;160(3):447-60. doi: 10.1016/j.cell.2015.01.002.Norman J.M., Handley S. A., Baldridge M. T. et al. Disease-specific alterations in the enteric virome in inflammatory bowel disease. Cell. 2015 Jan 29;160(3):447-60. doi: 10.1016/j.cell.2015.01.002.Zuo T., Lu X. J., Zhang Y., Cheung C. P. et al. Gut mucosal virome alterations in ulcerative colitis. Gut. 2019 Jul;68(7):1169-1179. doi: 10.1136/gutjnl-2018-318131.Zuo T., Lu X. J., Zhang Y., Cheung C. P. et al. Gut mucosal virome alterations in ulcerative colitis. Gut. 2019 Jul;68(7):1169-1179. doi: 10.1136/gutjnl-2018-318131.Clooney A.G., Sutton T. D.S., Shkoporov A. N., Holohan R. K. et al. Whole-Virome Analysis Sheds Light on Viral Dark Matter in Inflammatory Bowel Disease. Cell Host Microbe. 2019 Dec 11;26(6):764-778.e5. doi: 10.1016/j.chom.2019.10.009.Clooney A.G., Sutton T. D.S., Shkoporov A. N., Holohan R. K. et al. Whole-Virome Analysis Sheds Light on Viral Dark Matter in Inflammatory Bowel Disease. Cell Host Microbe. 2019 Dec 11;26(6):764-778.e5. doi: 10.1016/j.chom.2019.10.009.Blais Lecours P., Marsolais D., Cormier Y., Berberi M., Haché C., Bourdages R., Duchaine C. Increased prevalence of Methanosphaera stadtmanae in inflammatory bowel diseases. PLoS One. 2014 Feb 3;9(2): e87734. doi: 10.1371/journal.pone.0087734.Blais Lecours P., Marsolais D., Cormier Y., Berberi M., Haché C., Bourdages R., Duchaine C. Increased prevalence of Methanosphaera stadtmanae in inflammatory bowel diseases. PLoS One. 2014 Feb 3;9(2): e87734. doi: 10.1371/journal.pone.0087734.Sitkin S.I., Avalueva E. B., Bakulin I. G., Skalinskaya M. I., Vorobyev S. L., Pavlova E. Yu., Khavkin A. I. The role of bacterial, fungal, and viral infections in the pathogenesis of inflammatory bowel disease. Infekc. bolezni (Infectious Diseases). 2023; 21(2): 64-81. (In Russ.) doi: 10.20953/1729-9225-2023-2-64-81.@@ Ситкин С. И., Авалуева Е. Б., Бакулин И. Г., Скалинская М. И., Воробьёв С. Л., Павлова Е. Ю., Хавкин А. И. Роль бактериальных, грибковых и вирусных инфекций в патогенезе воспалительных заболеваний кишечника. Инфекционные болезни. 2023; 21(2): 64-81. doi: 10.20953/1729-9225-2023-2-64-81.Sitkin S.I., Avalueva E. B., Bakulin I. G., Skalinskaya M. I., Vorobyev S. L., Pavlova E. Yu., Khavkin A. I. The role of bacterial, fungal, and viral infections in the pathogenesis of inflammatory bowel disease. Infekc. bolezni (Infectious Diseases). 2023; 21(2): 64-81. (In Russ.) doi: 10.20953/1729-9225-2023-2-64-81.@@ Ситкин С. И., Авалуева Е. Б., Бакулин И. Г., Скалинская М. И., Воробьёв С. Л., Павлова Е. Ю., Хавкин А. И. Роль бактериальных, грибковых и вирусных инфекций в патогенезе воспалительных заболеваний кишечника. Инфекционные болезни. 2023; 21(2): 64-81. doi: 10.20953/1729-9225-2023-2-64-81.Römkens T.E., Bulte G. J., Nissen L. H., Drenth J. P. Cytomegalovirus in inflammatory bowel disease: A systematic review. World J Gastroenterol. 2016 Jan 21;22(3):1321-30. doi: 10.3748/wjg.v22.i3.1321.Römkens T.E., Bulte G. J., Nissen L. H., Drenth J. P. Cytomegalovirus in inflammatory bowel disease: A systematic review. World J Gastroenterol. 2016 Jan 21;22(3):1321-30. doi: 10.3748/wjg.v22.i3.1321.Mourad F.H., Hashash J. G., Kariyawasam V. C., Leong R. W. Ulcerative Colitis and Cytomegalovirus Infection: From A to Z. J Crohns Colitis. 2020 Sep 7;14(8):1162-1171. doi: 10.1093/ecco-jcc/jjaa036.Mourad F.H., Hashash J. G., Kariyawasam V. C., Leong R. W. Ulcerative Colitis and Cytomegalovirus Infection: From A to Z. J Crohns Colitis. 2020 Sep 7;14(8):1162-1171. doi: 10.1093/ecco-jcc/jjaa036.Axelrad J.E., Cadwell K. H., Colombel J. F., Shah S. C. The role of gastrointestinal pathogens in inflammatory bowel disease: a systematic review. Therap Adv Gastroenterol. 2021 Mar 31;14:17562848211004493. doi: 10.1177/17562848211004493.Axelrad J.E., Cadwell K. H., Colombel J. F., Shah S. C. The role of gastrointestinal pathogens in inflammatory bowel disease: a systematic review. Therap Adv Gastroenterol. 2021 Mar 31;14:17562848211004493. doi: 10.1177/17562848211004493.Linton M.S., Kroeker K., Fedorak D., Dieleman L., Fedorak R. N. Prevalence of Epstein-Barr Virus in a population of patients with inflammatory bowel disease: a prospective cohort study. Aliment Pharmacol Ther. 2013 Nov;38(10):1248-54. doi: 10.1111/apt.12503.Linton M.S., Kroeker K., Fedorak D., Dieleman L., Fedorak R. N. Prevalence of Epstein-Barr Virus in a population of patients with inflammatory bowel disease: a prospective cohort study. Aliment Pharmacol Ther. 2013 Nov;38(10):1248-54. doi: 10.1111/apt.12503.Dimitroulia E., Pitiriga V. C., Piperaki E. T., Spanakis N. E., Tsakris A. Inflammatory bowel disease exacerbation associated with Epstein-Barr virus infection. Dis Colon Rectum. 2013 Mar;56(3):322-7. doi: 10.1097/DCR.0b013e31827cd02c.Dimitroulia E., Pitiriga V. C., Piperaki E. T., Spanakis N. E., Tsakris A. Inflammatory bowel disease exacerbation associated with Epstein-Barr virus infection. Dis Colon Rectum. 2013 Mar;56(3):322-7. doi: 10.1097/DCR.0b013e31827cd02c.Nissen LH, Nagtegaal ID, de Jong DJ, Kievit W, Derikx LA, Groenen PJ, van Krieken JH, Hoentjen F. Epstein-Barr virus in inflammatory bowel disease: the spectrum of intestinal lymphoproliferative disorders. J Crohns Colitis. 2015 May;9(5):398-403. doi: 10.1093/ecco-jcc/jjv040.Nissen LH, Nagtegaal ID, de Jong DJ, Kievit W, Derikx LA, Groenen PJ, van Krieken JH, Hoentjen F. Epstein-Barr virus in inflammatory bowel disease: the spectrum of intestinal lymphoproliferative disorders. J Crohns Colitis. 2015 May;9(5):398-403. doi: 10.1093/ecco-jcc/jjv040.Wei H.T., Xue X. W., Ling Q., Wang P. Y., Zhou W. X. Positive correlation between latent Epstein-Barr virus infection and severity of illness in inflammatory bowel disease patients. World J Gastrointest Surg. 2023 Mar 27;15(3):420-429. doi: 10.4240/wjgs.v15.i3.420.Wei H.T., Xue X. W., Ling Q., Wang P. Y., Zhou W. X. Positive correlation between latent Epstein-Barr virus infection and severity of illness in inflammatory bowel disease patients. World J Gastrointest Surg. 2023 Mar 27;15(3):420-429. doi: 10.4240/wjgs.v15.i3.420.Axelrad J.E., Joelson A., Green P. H.R., Lawlor G., Lichtiger S., Cadwell K., Lebwohl B. Enteric Infections Are Common in Patients with Flares of Inflammatory Bowel Disease. Am J Gastroenterol. 2018 Oct;113(10):1530-1539. doi: 10.1038/s41395-018-0211-8.Axelrad J.E., Joelson A., Green P. H.R., Lawlor G., Lichtiger S., Cadwell K., Lebwohl B. Enteric Infections Are Common in Patients with Flares of Inflammatory Bowel Disease. Am J Gastroenterol. 2018 Oct;113(10):1530-1539. doi: 10.1038/s41395-018-0211-8.Tarris G., de Rougemont A., Estienney M. et al. Specific Norovirus Interaction with Lewis x and Lewis a on Human Intestinal Inflammatory Mucosa during Refractory Inflammatory Bowel Disease. mSphere. 2021 Jan 13;6(1): e01185-20. doi: 10.1128/mSphere.01185-20.Tarris G., de Rougemont A., Estienney M. et al. Specific Norovirus Interaction with Lewis x and Lewis a on Human Intestinal Inflammatory Mucosa during Refractory Inflammatory Bowel Disease. mSphere. 2021 Jan 13;6(1): e01185-20. doi: 10.1128/mSphere.01185-20.Adiliaghdam F., Amatullah H., Digumarthi S. et al. Human enteric viruses autonomously shape inflammatory bowel disease phenotype through divergent innate immunomodulation. Sci Immunol. 2022 Apr 8;7(70): eabn6660. doi: 10.1126/sciimmunol.abn6660.Adiliaghdam F., Amatullah H., Digumarthi S. et al. Human enteric viruses autonomously shape inflammatory bowel disease phenotype through divergent innate immunomodulation. Sci Immunol. 2022 Apr 8;7(70): eabn6660. doi: 10.1126/sciimmunol.abn6660.Calabrese E., Zorzi F., Monteleone G., Del Vecchio Blanco G. Onset of ulcerative colitis during SARS-CoV-2 infection. Dig Liver Dis. 2020 Nov;52(11):1228-1229. doi: 10.1016/j.dld.2020.06.003.Calabrese E., Zorzi F., Monteleone G., Del Vecchio Blanco G. Onset of ulcerative colitis during SARS-CoV-2 infection. Dig Liver Dis. 2020 Nov;52(11):1228-1229. doi: 10.1016/j.dld.2020.06.003.Taxonera C., Fisac J., Alba C. Can COVID-19 Trigger De Novo Inflammatory Bowel Disease? Gastroenterology. 2021 Mar;160(4):1029-1030. doi: 10.1053/j.gastro.2020.11.026.Taxonera C., Fisac J., Alba C. Can COVID-19 Trigger De Novo Inflammatory Bowel Disease? Gastroenterology. 2021 Mar;160(4):1029-1030. doi: 10.1053/j.gastro.2020.11.026.Imperatore N., Bennato R., D’Avino A., Lombardi G., Manguso F. SARS-CoV-2 as a Trigger for De Novo Ulcerative Colitis. Inflamm Bowel Dis. 2021 Jun 15;27(7): e87-e88. doi: 10.1093/ibd/izab040.Imperatore N., Bennato R., D’Avino A., Lombardi G., Manguso F. SARS-CoV-2 as a Trigger for De Novo Ulcerative Colitis. Inflamm Bowel Dis. 2021 Jun 15;27(7): e87-e88. doi: 10.1093/ibd/izab040.Tursi A., Nenna R. COVID-19 as a Trigger for De Novo Crohn’s Disease. Inflamm Bowel Dis. 2022 Jun 3;28(6): e76-e77. doi: 10.1093/ibd/izab298.Tursi A., Nenna R. COVID-19 as a Trigger for De Novo Crohn’s Disease. Inflamm Bowel Dis. 2022 Jun 3;28(6): e76-e77. doi: 10.1093/ibd/izab298.Preziosi N.A., Rizvi A. H., Feerick J. D., Mandelia C. De Novo Pediatric Ulcerative Colitis Triggered by SARS-CoV-2 Infection: a Tale of 2 Sisters. Inflamm Bowel Dis. 2022 Oct 3;28(10):1623-1625. doi: 10.1093/ibd/izac142.Preziosi N.A., Rizvi A. H., Feerick J. D., Mandelia C. De Novo Pediatric Ulcerative Colitis Triggered by SARS-CoV-2 Infection: a Tale of 2 Sisters. Inflamm Bowel Dis. 2022 Oct 3;28(10):1623-1625. doi: 10.1093/ibd/izac142.Morita A., Imagawa K., Tagawa M., Sakamoto N., Takada H. Case report: Immunological characteristics of de novo ulcerative colitis in a child post COVID-19. Front Immunol. 2023 Feb 16;14:1107808. doi: 10.3389/fimmu.2023.1107808.Morita A., Imagawa K., Tagawa M., Sakamoto N., Takada H. Case report: Immunological characteristics of de novo ulcerative colitis in a child post COVID-19. Front Immunol. 2023 Feb 16;14:1107808. doi: 10.3389/fimmu.2023.1107808.Sweeny K.F., Zhang Y. J., Crume B., Martz C. A., Blessing M. M., Kahn S. A. Inflammatory Bowel Disease Presenting With Concurrent COVID-19 Multisystem Inflammatory Syndrome. Pediatrics. 2021 Apr;147(4): e2020027763. doi: 10.1542/peds.2020-027763.Sweeny K.F., Zhang Y. J., Crume B., Martz C. A., Blessing M. M., Kahn S. A. Inflammatory Bowel Disease Presenting With Concurrent COVID-19 Multisystem Inflammatory Syndrome. Pediatrics. 2021 Apr;147(4): e2020027763. doi: 10.1542/peds.2020-027763.Krawiec P., Opoka-Winiarska V., Pac-Kożuchowska E. Is It Inflammatory Bowel Disease Flare or Pediatric Inflammatory Multisystem Syndrome Temporally Associated with COVID-19? J Clin Med. 2022 May 13;11(10):2765. doi: 10.3390/jcm11102765.Krawiec P., Opoka-Winiarska V., Pac-Kożuchowska E. Is It Inflammatory Bowel Disease Flare or Pediatric Inflammatory Multisystem Syndrome Temporally Associated with COVID-19? J Clin Med. 2022 May 13;11(10):2765. doi: 10.3390/jcm11102765.Dvornikova K.A., Bystrova E. Y., Churilov L. P., Lerner A. Pathogenesis of the inflammatory bowel disease in context of SARS-COV-2 infection. Mol Biol Rep. 2021 Jul;48(7):5745-5758. doi: 10.1007/s11033-021-06565-w.Dvornikova K.A., Bystrova E. Y., Churilov L. P., Lerner A. Pathogenesis of the inflammatory bowel disease in context of SARS-COV-2 infection. Mol Biol Rep. 2021 Jul;48(7):5745-5758. doi: 10.1007/s11033-021-06565-w.Zhao C., Zhao W. NLRP3 Inflammasome-A Key Player in Antiviral Responses. Front Immunol. 2020 Feb 18;11:211. doi: 10.3389/fimmu.2020.00211.Zhao C., Zhao W. NLRP3 Inflammasome-A Key Player in Antiviral Responses. Front Immunol. 2020 Feb 18;11:211. doi: 10.3389/fimmu.2020.00211.Lin L., Jiang X., Zhang Z. et al. Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection. Gut. 2020 Jun;69(6):997-1001. doi: 10.1136/gutjnl-2020-321013.Lin L., Jiang X., Zhang Z. et al. Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection. Gut. 2020 Jun;69(6):997-1001. doi: 10.1136/gutjnl-2020-321013.Buscarini E., Manfredi G., Brambilla G. et al. GI symptoms as early signs of COVID-19 in hospitalised Italian patients. Gut. 2020 Aug;69(8):1547-1548. doi: 10.1136/gutjnl-2020-321434.Buscarini E., Manfredi G., Brambilla G. et al. GI symptoms as early signs of COVID-19 in hospitalised Italian patients. Gut. 2020 Aug;69(8):1547-1548. doi: 10.1136/gutjnl-2020-321434.Massimino L., Palmieri O., Facoetti A. et al. Gut virome-colonising Orthohepadnavirus genus is associated with ulcerative colitis pathogenesis and induces intestinal inflammation in vivo. Gut. 2023 Oct;72(10):1838-1847. doi: 10.1136/gutjnl-2022-328375.Massimino L., Palmieri O., Facoetti A. et al. Gut virome-colonising Orthohepadnavirus genus is associated with ulcerative colitis pathogenesis and induces intestinal inflammation in vivo. Gut. 2023 Oct;72(10):1838-1847. doi: 10.1136/gutjnl-2022-328375.Ghavami S.B., Rostami E., Sephay A. A., Shahrokh S., Balaii H., Aghdaei H. A., Zali M. R. Alterations of the human gut Methanobrevibacter smithii as a biomarker for inflammatory bowel diseases. Microb Pathog. 2018 Apr;117:285-289. doi: 10.1016/j.micpath.2018.01.029.Ghavami S.B., Rostami E., Sephay A. A., Shahrokh S., Balaii H., Aghdaei H. A., Zali M. R. Alterations of the human gut Methanobrevibacter smithii as a biomarker for inflammatory bowel diseases. Microb Pathog. 2018 Apr;117:285-289. doi: 10.1016/j.micpath.2018.01.029.Tong M., Li X., Wegener Parfrey L. et al. A modular organization of the human intestinal mucosal microbiota and its association with inflammatory bowel disease. PLoS One. 2013 Nov 19;8(11): e80702. doi: 10.1371/journal.pone.0080702.Tong M., Li X., Wegener Parfrey L. et al. A modular organization of the human intestinal mucosal microbiota and its association with inflammatory bowel disease. PLoS One. 2013 Nov 19;8(11): e80702. doi: 10.1371/journal.pone.0080702.Vester-Andersen M.K., Mirsepasi-Lauridsen H.C., Prosberg M. V. et al. Increased abundance of proteobacteria in aggressive Crohn’s disease seven years after diagnosis. Sci Rep. 2019 Sep 17;9(1):13473. doi: 10.1038/s41598-019-49833-3.Vester-Andersen M.K., Mirsepasi-Lauridsen H.C., Prosberg M. V. et al. Increased abundance of proteobacteria in aggressive Crohn’s disease seven years after diagnosis. Sci Rep. 2019 Sep 17;9(1):13473. doi: 10.1038/s41598-019-49833-3.Braun T., Di Segni A., BenShoshan M. et al. Individualized Dynamics in the Gut Microbiota Precede Crohn’s Disease Flares. Am J Gastroenterol. 2019 Jul;114(7):1142-1151. doi: 10.14309/ajg.0000000000000136.Braun T., Di Segni A., BenShoshan M. et al. Individualized Dynamics in the Gut Microbiota Precede Crohn’s Disease Flares. Am J Gastroenterol. 2019 Jul;114(7):1142-1151. doi: 10.14309/ajg.0000000000000136.Sun M., Du B., Shi Y., Lu Y., Zhou Y., Liu B.Combined Signature of the Fecal Microbiome and Plasma Metabolome in Patients with Ulcerative Colitis. Med Sci Monit. 2019 May 5;25:3303-3315. doi: 10.12659/MSM.916009.Sun M., Du B., Shi Y., Lu Y., Zhou Y., Liu B.Combined Signature of the Fecal Microbiome and Plasma Metabolome in Patients with Ulcerative Colitis. Med Sci Monit. 2019 May 5;25:3303-3315. doi: 10.12659/MSM.916009.Park S.K., Kim H. N., Choi C. H., Im J. P. et al. Differentially Abundant Bacterial Taxa Associated with Prognostic Variables of Crohn’s Disease: Results from the IMPACT Study. J Clin Med. 2020 Jun 5;9(6):1748. doi: 10.3390/jcm9061748.Park S.K., Kim H. N., Choi C. H., Im J. P. et al. Differentially Abundant Bacterial Taxa Associated with Prognostic Variables of Crohn’s Disease: Results from the IMPACT Study. J Clin Med. 2020 Jun 5;9(6):1748. doi: 10.3390/jcm9061748.Zhang J., Chen S. L., Li L. B. Correlation between intestinal flora and serum inflammatory factors in patients with Crohn’s disease. Eur Rev Med Pharmacol Sci. 2017 Nov;21(21):4913-4917. PMID: 29164569.Zhang J., Chen S. L., Li L. B. Correlation between intestinal flora and serum inflammatory factors in patients with Crohn’s disease. Eur Rev Med Pharmacol Sci. 2017 Nov;21(21):4913-4917. PMID: 29164569.Wang W., Chen L., Zhou R., Wang X., Song L., Huang S., Wang G., Xia B. Increased proportions of Bifidobacterium and the Lactobacillus group and loss of butyrate-producing bacteria in inflammatory bowel disease. J Clin Microbiol. 2014 Feb;52(2):398-406. doi: 10.1128/JCM.01500-13.Wang W., Chen L., Zhou R., Wang X., Song L., Huang S., Wang G., Xia B. Increased proportions of Bifidobacterium and the Lactobacillus group and loss of butyrate-producing bacteria in inflammatory bowel disease. J Clin Microbiol. 2014 Feb;52(2):398-406. doi: 10.1128/JCM.01500-13.Galazzo G., Tedjo D. I., Wintjens D. S.J. et al. Faecal Microbiota Dynamics and their Relation to Disease Course in Crohn’s Disease. J Crohns Colitis. 2019 Sep 27;13(10):1273-1282. doi: 10.1093/ecco-jcc/jjz049.Galazzo G., Tedjo D. I., Wintjens D. S.J. et al. Faecal Microbiota Dynamics and their Relation to Disease Course in Crohn’s Disease. J Crohns Colitis. 2019 Sep 27;13(10):1273-1282. doi: 10.1093/ecco-jcc/jjz049.Boland K., Bedrani L., Turpin W., Kabakchiev B. et al. Persistent Diarrhea in Patients With Crohn’s Disease After Mucosal Healing Is Associated With Lower Diversity of the Intestinal Microbiome and Increased Dysbiosis. Clin Gastroenterol Hepatol. 2021 Feb;19(2):296-304.e3. doi: 10.1016/j.cgh.2020.03.044.Boland K., Bedrani L., Turpin W., Kabakchiev B. et al. Persistent Diarrhea in Patients With Crohn’s Disease After Mucosal Healing Is Associated With Lower Diversity of the Intestinal Microbiome and Increased Dysbiosis. Clin Gastroenterol Hepatol. 2021 Feb;19(2):296-304.e3. doi: 10.1016/j.cgh.2020.03.044.Borren N.Z., Plichta D., Joshi A. D., Bonilla G., Sadreyev R., Vlamakis H., Xavier R. J., Ananthakrishnan A. N. Multi-”-Omics” Profiling in Patients With Quiescent Inflammatory Bowel Disease Identifies Biomarkers Predicting Relapse. Inflamm Bowel Dis. 2020 Sep 18;26(10):1524-1532. doi: 10.1093/ibd/izaa183.Borren N.Z., Plichta D., Joshi A. D., Bonilla G., Sadreyev R., Vlamakis H., Xavier R. J., Ananthakrishnan A. N. Multi-”-Omics” Profiling in Patients With Quiescent Inflammatory Bowel Disease Identifies Biomarkers Predicting Relapse. Inflamm Bowel Dis. 2020 Sep 18;26(10):1524-1532. doi: 10.1093/ibd/izaa183.Tedjo D.I., Smolinska A., Savelkoul P. H., Masclee A. A., van Schooten F. J., Pierik M. J., Penders J., Jonkers D. M. The fecal microbiota as a biomarker for disease activity in Crohn’s disease. Sci Rep. 2016 Oct 13;6:35216. doi: 10.1038/srep35216.Tedjo D.I., Smolinska A., Savelkoul P. H., Masclee A. A., van Schooten F. J., Pierik M. J., Penders J., Jonkers D. M. The fecal microbiota as a biomarker for disease activity in Crohn’s disease. Sci Rep. 2016 Oct 13;6:35216. doi: 10.1038/srep35216.Pascal V., Pozuelo M., Borruel N. et al. A microbial signature for Crohn’s disease. Gut. 2017 May;66(5):813-822. doi: 10.1136/gutjnl-2016-313235.Pascal V., Pozuelo M., Borruel N. et al. A microbial signature for Crohn’s disease. Gut. 2017 May;66(5):813-822. doi: 10.1136/gutjnl-2016-313235.Rehman A., Rausch P., Wang J. et al. Geographical patterns of the standing and active human gut microbiome in health and IBD. Gut. 2016 Feb;65(2):238-48. doi: 10.1136/gutjnl-2014-308341.Rehman A., Rausch P., Wang J. et al. Geographical patterns of the standing and active human gut microbiome in health and IBD. Gut. 2016 Feb;65(2):238-48. doi: 10.1136/gutjnl-2014-308341.Wisittipanit N., Rangwala H., Sikaroodi M., Keshavarzian A., Mutlu E. A., Gillevet P. Classification methods for the analysis of LH-PCR data associated with inflammatory bowel disease patients.Int J Bioinform Res Appl. 2015;11(2):111-29. doi: 10.1504/IJBRA.2015.068087.Wisittipanit N., Rangwala H., Sikaroodi M., Keshavarzian A., Mutlu E. A., Gillevet P. Classification methods for the analysis of LH-PCR data associated with inflammatory bowel disease patients.Int J Bioinform Res Appl. 2015;11(2):111-29. doi: 10.1504/IJBRA.2015.068087.Lloyd-Price J., Arze C., Ananthakrishnan A. N., Schirmer M., Avila-Pacheco J., Poon T. W., Andrews E., Ajami N. J., Bonham K. S., Brislawn C. J., Casero D., Courtney H., Gonzalez A., Graeber T. G., Hall A. B., Lake K., Landers C. J., Mallick H., Plichta D. R., Prasad M., Rahnavard G., Sauk J., Shungin D., Vázquez-Baeza Y., White RA 3rd.; IBDMDB Investigators; Braun J., Denson L. A., Jansson J. K., Knight R., Kugathasan S., McGovern D.P.B., Petrosino J. F., Stappenbeck T. S., Winter H. S., Clish C. B., Franzosa E. A., Vlamakis H., Xavier R. J., Huttenhower C. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature. 2019 May;569(7758):655-662. doi: 10.1038/s41586-019-1237-9.Lloyd-Price J., Arze C., Ananthakrishnan A. N., Schirmer M., Avila-Pacheco J., Poon T. W., Andrews E., Ajami N. J., Bonham K. S., Brislawn C. J., Casero D., Courtney H., Gonzalez A., Graeber T. G., Hall A. B., Lake K., Landers C. J., Mallick H., Plichta D. R., Prasad M., Rahnavard G., Sauk J., Shungin D., Vázquez-Baeza Y., White RA 3rd.; IBDMDB Investigators; Braun J., Denson L. A., Jansson J. K., Knight R., Kugathasan S., McGovern D.P.B., Petrosino J. F., Stappenbeck T. S., Winter H. S., Clish C. B., Franzosa E. A., Vlamakis H., Xavier R. J., Huttenhower C. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature. 2019 May;569(7758):655-662. doi: 10.1038/s41586-019-1237-9.Butera A., Di Paola M., Vitali F., De Nitto D. et al. IL-13 mRNA Tissue Content Identifies Two Subsets of Adult Ulcerative Colitis Patients With Different Clinical and Mucosa-Associated Microbiota Profiles. J Crohns Colitis. 2020 Mar 13;14(3):369-380. doi: 10.1093/ecco-jcc/jjz154.Butera A., Di Paola M., Vitali F., De Nitto D. et al. IL-13 mRNA Tissue Content Identifies Two Subsets of Adult Ulcerative Colitis Patients With Different Clinical and Mucosa-Associated Microbiota Profiles. J Crohns Colitis. 2020 Mar 13;14(3):369-380. doi: 10.1093/ecco-jcc/jjz154.Rubbens P., Props R., Kerckhof F. M., Boon N., Waegeman W. Cytometric fingerprints of gut microbiota predict Crohn’s disease state. ISME J. 2021 Jan;15(1):354-358. doi: 10.1038/s41396-020-00762-4.Rubbens P., Props R., Kerckhof F. M., Boon N., Waegeman W. Cytometric fingerprints of gut microbiota predict Crohn’s disease state. ISME J. 2021 Jan;15(1):354-358. doi: 10.1038/s41396-020-00762-4.Xun Z., Zhang Q., Xu T., Chen N., Chen F. Dysbiosis and Ecotypes of the Salivary Microbiome Associated With Inflammatory Bowel Diseases and the Assistance in Diagnosis of Diseases Using Oral Bacterial Profiles. Front Microbiol. 2018 May 30;9:1136. doi: 10.3389/fmicb.2018.01136.Xun Z., Zhang Q., Xu T., Chen N., Chen F. Dysbiosis and Ecotypes of the Salivary Microbiome Associated With Inflammatory Bowel Diseases and the Assistance in Diagnosis of Diseases Using Oral Bacterial Profiles. Front Microbiol. 2018 May 30;9:1136. doi: 10.3389/fmicb.2018.01136.Said H.S., Suda W., Nakagome S. et al. Dysbiosis of salivary microbiota in inflammatory bowel disease and its association with oral immunological biomarkers. DNA Res. 2014 Feb;21(1):15-25. doi: 10.1093/dnares/dst037.Said H.S., Suda W., Nakagome S. et al. Dysbiosis of salivary microbiota in inflammatory bowel disease and its association with oral immunological biomarkers. DNA Res. 2014 Feb;21(1):15-25. doi: 10.1093/dnares/dst037.Qi Y., Zang S. Q., Wei J., Yu H. C., Yang Z., Wu H. M., Kang Y., Tao H., Yang M. F., Jin L., Zen K., Wang F. Y. High-throughput sequencing provides insights into oral microbiota dysbiosis in association with inflammatory bowel disease. Genomics. 2021 Jan;113(1 Pt 2):664-676. doi: 10.1016/j.ygeno.2020.09.063.Qi Y., Zang S. Q., Wei J., Yu H. C., Yang Z., Wu H. M., Kang Y., Tao H., Yang M. F., Jin L., Zen K., Wang F. Y. High-throughput sequencing provides insights into oral microbiota dysbiosis in association with inflammatory bowel disease. Genomics. 2021 Jan;113(1 Pt 2):664-676. doi: 10.1016/j.ygeno.2020.09.063.Zhang T., Kayani M. U.R., Hong L., Zhang C., Zhong J., Wang Z., Chen L. Dynamics of the Salivary Microbiome During Different Phases of Crohn’s Disease. Front Cell Infect Microbiol. 2020 Oct 6;10:544704. doi: 10.3389/fcimb.2020.544704.Zhang T., Kayani M. U.R., Hong L., Zhang C., Zhong J., Wang Z., Chen L. Dynamics of the Salivary Microbiome During Different Phases of Crohn’s Disease. Front Cell Infect Microbiol. 2020 Oct 6;10:544704. doi: 10.3389/fcimb.2020.544704.Gevers D., Kugathasan S., Denson L. A. et al. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe. 2014 Mar 12;15(3):382-392. doi: 10.1016/j.chom.2014.02.005.Gevers D., Kugathasan S., Denson L. A. et al. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe. 2014 Mar 12;15(3):382-392. doi: 10.1016/j.chom.2014.02.005.Molinero N., Taladrid D., Zorraquín-Peña I., de Celis M., Belda I., Mira A., Bartolomé B., Moreno-Arribas M. V. Ulcerative Colitis Seems to Imply Oral Microbiome Dysbiosis. Curr Issues Mol Biol. 2022 Mar 30;44(4):1513-1527. doi: 10.3390/cimb44040103.Molinero N., Taladrid D., Zorraquín-Peña I., de Celis M., Belda I., Mira A., Bartolomé B., Moreno-Arribas M. V. Ulcerative Colitis Seems to Imply Oral Microbiome Dysbiosis. Curr Issues Mol Biol. 2022 Mar 30;44(4):1513-1527. doi: 10.3390/cimb44040103.Abdullah N., Al-Marzooq F., Mohamad S., Abd Rahman N., Chi Ngo H., Perera Samaranayake L.Intraoral appliances for in situ oral biofilm growth: a systematic review. J Oral Microbiol. 2019 Aug 6;11(1):1647757. doi: 10.1080/20002297.2019.1647757.Abdullah N., Al-Marzooq F., Mohamad S., Abd Rahman N., Chi Ngo H., Perera Samaranayake L.Intraoral appliances for in situ oral biofilm growth: a systematic review. J Oral Microbiol. 2019 Aug 6;11(1):1647757. doi: 10.1080/20002297.2019.1647757.Elmaghrawy K., Hussey S., Moran G. P. The Oral Microbiome in Pediatric IBD: A Source of Pathobionts or Biomarkers? Front Pediatr. 2021 Jan 21;8:620254. doi: 10.3389/fped.2020.620254.Elmaghrawy K., Hussey S., Moran G. P. The Oral Microbiome in Pediatric IBD: A Source of Pathobionts or Biomarkers? Front Pediatr. 2021 Jan 21;8:620254. doi: 10.3389/fped.2020.620254.Read E., Curtis M. A., Neves J. F. The role of oral bacteria in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021 Oct;18(10):731-742. doi: 10.1038/s41575-021-00488-4.Read E., Curtis M. A., Neves J. F. The role of oral bacteria in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021 Oct;18(10):731-742. doi: 10.1038/s41575-021-00488-4.Cecoro G., Annunziata M., Iuorio M. T., Nastri L., Guida L. Periodontitis, Low-Grade Inflammation and Systemic Health: A Scoping Review. Medicina (Kaunas). 2020 May 30;56(6):272. doi: 10.3390/medicina56060272.Cecoro G., Annunziata M., Iuorio M. T., Nastri L., Guida L. Periodontitis, Low-Grade Inflammation and Systemic Health: A Scoping Review. Medicina (Kaunas). 2020 May 30;56(6):272. doi: 10.3390/medicina56060272.Kitamoto S., Nagao-Kitamoto H., Jiao Y. et al. The Intermucosal Connection between the Mouth and Gut in Commensal Pathobiont-Driven Colitis. Cell. 2020 Jul 23;182(2):447-462.e14. doi: 10.1016/j.cell.2020.05.048.Kitamoto S., Nagao-Kitamoto H., Jiao Y. et al. The Intermucosal Connection between the Mouth and Gut in Commensal Pathobiont-Driven Colitis. Cell. 2020 Jul 23;182(2):447-462.e14. doi: 10.1016/j.cell.2020.05.048.Atarashi K., Suda W., Luo C. et al. Ectopic colonization of oral bacteria in the intestine drives TH1 cell induction and inflammation. Science. 2017 Oct 20;358(6361):359-365. doi: 10.1126/science.aan4526.Atarashi K., Suda W., Luo C. et al. Ectopic colonization of oral bacteria in the intestine drives TH1 cell induction and inflammation. Science. 2017 Oct 20;358(6361):359-365. doi: 10.1126/science.aan4526.Al-Rawi N., Al-Marzooq F. The Relation between Periodontopathogenic Bacterial Levels and Resistin in the Saliva of Obese Type 2 Diabetic Patients. J Diabetes Res. 2017;2017:2643079. doi: 10.1155/2017/2643079.Al-Rawi N., Al-Marzooq F. The Relation between Periodontopathogenic Bacterial Levels and Resistin in the Saliva of Obese Type 2 Diabetic Patients. J Diabetes Res. 2017;2017:2643079. doi: 10.1155/2017/2643079.Al-Rawi N.H., Al-Marzooq F., Al-Nuaimi A.S., Hachim M. Y., Hamoudi R. Salivary microRNA 155, 146a/b and 203: A pilot study for potentially non-invasive diagnostic biomarkers of periodontitis and diabetes mellitus. PLoS One. 2020 Aug 5;15(8): e0237004. doi: 10.1371/journal.pone.0237004.Al-Rawi N.H., Al-Marzooq F., Al-Nuaimi A.S., Hachim M. Y., Hamoudi R. Salivary microRNA 155, 146a/b and 203: A pilot study for potentially non-invasive diagnostic biomarkers of periodontitis and diabetes mellitus. PLoS One. 2020 Aug 5;15(8): e0237004. doi: 10.1371/journal.pone.0237004.van der Sloot K. W.J., Voskuil M. D., Blokzijl T., Dinkla A. et al. Isotype-specific Antibody Responses to Mycobacterium avium paratuberculosis Antigens Are Associated With the Use of Biologic Therapy in Inflammatory Bowel Disease. J Crohns Colitis. 2021 Aug 2;15(8):1253-1263. doi: 10.1093/ecco-jcc/jjaa263.van der Sloot K. W.J., Voskuil M. D., Blokzijl T., Dinkla A. et al. Isotype-specific Antibody Responses to Mycobacterium avium paratuberculosis Antigens Are Associated With the Use of Biologic Therapy in Inflammatory Bowel Disease. J Crohns Colitis. 2021 Aug 2;15(8):1253-1263. doi: 10.1093/ecco-jcc/jjaa263.Fernandes J., Su W., Rahat-Rozenbloom S., Wolever T. M., Comelli E. M. Adiposity, gut microbiota and faecal short chain fatty acids are linked in adult humans. Nutr Diabetes. 2014 Jun 30;4(6): e121. doi: 10.1038/nutd.2014.23.Fernandes J., Su W., Rahat-Rozenbloom S., Wolever T. M., Comelli E. M. Adiposity, gut microbiota and faecal short chain fatty acids are linked in adult humans. Nutr Diabetes. 2014 Jun 30;4(6): e121. doi: 10.1038/nutd.2014.23.Khatib M. The Impact of Food Structure and Promoting Short Chain Fatty Acids Production on Energy Home-ostasis and Appetite Regulation. London. Imperial College. 2019.Khatib M. The Impact of Food Structure and Promoting Short Chain Fatty Acids Production on Energy Home-ostasis and Appetite Regulation. London. Imperial College. 2019.Deleu S., Machiels K., Raes J., Verbeke K., Vermeire S. Short chain fatty acids and its producing organisms: An overlooked therapy for IBD? EBioMedicine. 2021 Apr;66:103293. doi: 10.1016/j.ebiom.2021.103293.Deleu S., Machiels K., Raes J., Verbeke K., Vermeire S. Short chain fatty acids and its producing organisms: An overlooked therapy for IBD? EBioMedicine. 2021 Apr;66:103293. doi: 10.1016/j.ebiom.2021.103293.Huda-Faujan N., Abdulamir A. S., Fatimah A. B., Anas O. M., Shuhaimi M., Yazid A. M., Loong Y. Y. The impact of the level of the intestinal short chain Fatty acids in inflammatory bowel disease patients versus healthy subjects. Open Biochem J. 2010 May 13;4:53-8. doi: 10.2174/1874091X01004010053.Huda-Faujan N., Abdulamir A. S., Fatimah A. B., Anas O. M., Shuhaimi M., Yazid A. M., Loong Y. Y. The impact of the level of the intestinal short chain Fatty acids in inflammatory bowel disease patients versus healthy subjects. Open Biochem J. 2010 May 13;4:53-8. doi: 10.2174/1874091X01004010053.Gonçalves P., Araújo J. R., Di Santo J. P. A Cross-Talk Between Microbiota-Derived Short-Chain Fatty Acids and the Host Mucosal Immune System Regulates Intestinal Homeostasis and Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 Feb 15;24(3):558-572. doi: 10.1093/ibd/izx029.Gonçalves P., Araújo J. R., Di Santo J. P. A Cross-Talk Between Microbiota-Derived Short-Chain Fatty Acids and the Host Mucosal Immune System Regulates Intestinal Homeostasis and Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 Feb 15;24(3):558-572. doi: 10.1093/ibd/izx029.Tan J., McKenzie C., Potamitis M., Thorburn A. N., Mackay C. R., Macia L. The role of short-chain fatty acids in health and disease. Adv Immunol. 2014;121:91-119. doi: 10.1016/B978-0-12-800100-4.00003-9.Tan J., McKenzie C., Potamitis M., Thorburn A. N., Mackay C. R., Macia L. The role of short-chain fatty acids in health and disease. Adv Immunol. 2014;121:91-119. doi: 10.1016/B978-0-12-800100-4.00003-9.Tan Y., Zou K. F., Qian W., Chen S., Hou X. H. Expression and implication of toll-like receptors TLR2, TLR4 and TLR9 in colonic mucosa of patients with ulcerative colitis. J Huazhong Univ Sci Technolog Med Sci. 2014 Oct;34(5):785-790. doi: 10.1007/s11596-014-1353-6.Tan Y., Zou K. F., Qian W., Chen S., Hou X. H. Expression and implication of toll-like receptors TLR2, TLR4 and TLR9 in colonic mucosa of patients with ulcerative colitis. J Huazhong Univ Sci Technolog Med Sci. 2014 Oct;34(5):785-790. doi: 10.1007/s11596-014-1353-6.Parada Venegas D., De la Fuente M. K., Landskron G., González M. J., Quera R., Dijkstra G., Harmsen H. J.M., Faber K. N., Hermoso M. A. Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases. Front Immunol. 2019 Mar 11;10:277. doi: 10.3389/fimmu.2019.00277.Parada Venegas D., De la Fuente M. K., Landskron G., González M. J., Quera R., Dijkstra G., Harmsen H. J.M., Faber K. N., Hermoso M. A. Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases. Front Immunol. 2019 Mar 11;10:277. doi: 10.3389/fimmu.2019.00277.Kussmann M., Stover P. J. Nutrigenomics and Proteomics in Health and Disease: Towards a Systems-Level Un-derstanding of Gene-Diet Interactions. Oxford. John Wiley & Sons. 2017.Kussmann M., Stover P. J. Nutrigenomics and Proteomics in Health and Disease: Towards a Systems-Level Un-derstanding of Gene-Diet Interactions. Oxford. John Wiley & Sons. 2017.Suskind D. L. Nutrition in Immune Balance (NIMBAL) Therapy: Using Diet to Treat Inflammatory Bowel Dis-ease. Nimbal Publishing. 2015.Suskind D. L. Nutrition in Immune Balance (NIMBAL) Therapy: Using Diet to Treat Inflammatory Bowel Dis-ease. Nimbal Publishing. 2015.Kakodkar S., Farooqui A. J., Mikolaitis S. L., Mutlu E. A. The Specific Carbohydrate Diet for Inflammatory Bowel Disease: A Case Series. J Acad Nutr Diet. 2015 Aug;115(8):1226-32. doi: 10.1016/j.jand.2015.04.016.Kakodkar S., Farooqui A. J., Mikolaitis S. L., Mutlu E. A. The Specific Carbohydrate Diet for Inflammatory Bowel Disease: A Case Series. J Acad Nutr Diet. 2015 Aug;115(8):1226-32. doi: 10.1016/j.jand.2015.04.016.Elsaygh H., Alhafez I., Jaber M., Al-Rasheed M., Zaher A., ElSaygh J. A Literature Review of Major Clinical Trials That Contributed to Treatment Protocols of Irritable Bowel Syndrome With Diarrhea. Cureus. 2022 Jun 19;14(6): e26092. doi: 10.7759/cureus.26092.Elsaygh H., Alhafez I., Jaber M., Al-Rasheed M., Zaher A., ElSaygh J. A Literature Review of Major Clinical Trials That Contributed to Treatment Protocols of Irritable Bowel Syndrome With Diarrhea. Cureus. 2022 Jun 19;14(6): e26092. doi: 10.7759/cureus.26092.Gibson P. R. The evidence base for efficacy of the low FODMAP diet in irritable bowel syndrome: is it ready for prime time as a first-line therapy? J Gastroenterol Hepatol. 2017 Mar;32 Suppl 1:32-35. doi: 10.1111/jgh.13693.Gibson P. R. The evidence base for efficacy of the low FODMAP diet in irritable bowel syndrome: is it ready for prime time as a first-line therapy? J Gastroenterol Hepatol. 2017 Mar;32 Suppl 1:32-35. doi: 10.1111/jgh.13693.Barrett J. S. How to institute the low-FODMAP diet. J Gastroenterol Hepatol. 2017 Mar;32 Suppl 1:8-10. doi: 10.1111/jgh.13686.Barrett J. S. How to institute the low-FODMAP diet. J Gastroenterol Hepatol. 2017 Mar;32 Suppl 1:8-10. doi: 10.1111/jgh.13686.Adamji M., Day A. S. An overview of the role of exclusive enteral nutrition for complicated Crohn’s disease.Intest Res. 2019 Apr;17(2):171-176. doi: 10.5217/ir.2018.00079.Adamji M., Day A. S. An overview of the role of exclusive enteral nutrition for complicated Crohn’s disease.Intest Res. 2019 Apr;17(2):171-176. doi: 10.5217/ir.2018.00079.Gubatan J., Boye T. L., Temby M., Sojwal R. S., Holman D. R., Sinha S. R., Rogalla S. R., Nielsen O. H. Gut Microbiome in Inflammatory Bowel Disease: Role in Pathogenesis, Dietary Modulation, and Colitis-Associated Colon Cancer. Microorganisms. 2022 Jul 7;10(7):1371. doi: 10.3390/microorganisms10071371.Gubatan J., Boye T. L., Temby M., Sojwal R. S., Holman D. R., Sinha S. R., Rogalla S. R., Nielsen O. H. Gut Microbiome in Inflammatory Bowel Disease: Role in Pathogenesis, Dietary Modulation, and Colitis-Associated Colon Cancer. Microorganisms. 2022 Jul 7;10(7):1371. doi: 10.3390/microorganisms10071371.Rizzello F., Spisni E., Giovanardi E., Imbesi V., Salice M., Alvisi P., Valerii M. C., Gionchetti P. Implications of the Westernized Diet in the Onset and Progression of IBD. Nutrients. 2019 May 8;11(5):1033. doi: 10.3390/nu11051033.Rizzello F., Spisni E., Giovanardi E., Imbesi V., Salice M., Alvisi P., Valerii M. C., Gionchetti P. Implications of the Westernized Diet in the Onset and Progression of IBD. Nutrients. 2019 May 8;11(5):1033. doi: 10.3390/nu11051033.Chiba M., Nakane K., Komatsu M. Westernized Diet is the Most Ubiquitous Environmental Factor in Inflammatory Bowel Disease. Perm J. 2019;23:18-107. doi: 10.7812/TPP/18-107.Chiba M., Nakane K., Komatsu M. Westernized Diet is the Most Ubiquitous Environmental Factor in Inflammatory Bowel Disease. Perm J. 2019;23:18-107. doi: 10.7812/TPP/18-107.Lee J.E., Kim K. S., Koh H., Lee D. W., Kang N. J. Diet-Induced Host-Microbe Interactions: Personalized Diet Strategies for Improving Inflammatory Bowel Disease. Curr Dev Nutr. 2022 Jun 25;6(8): nzac110. doi: 10.1093/cdn/nzac110.Lee J.E., Kim K. S., Koh H., Lee D. W., Kang N. J. Diet-Induced Host-Microbe Interactions: Personalized Diet Strategies for Improving Inflammatory Bowel Disease. Curr Dev Nutr. 2022 Jun 25;6(8): nzac110. doi: 10.1093/cdn/nzac110.Constante M., Fragoso G., Calvé A., Samba-Mondonga M., Santos M. M. Dietary Heme Induces Gut Dysbiosis, Aggravates Colitis, and Potentiates the Development of Adenomas in Mice. Front Microbiol. 2017 Sep 21;8:1809. doi: 10.3389/fmicb.2017.01809.Constante M., Fragoso G., Calvé A., Samba-Mondonga M., Santos M. M. Dietary Heme Induces Gut Dysbiosis, Aggravates Colitis, and Potentiates the Development of Adenomas in Mice. Front Microbiol. 2017 Sep 21;8:1809. doi: 10.3389/fmicb.2017.01809.Hu S., Mok J., Gowans M., Ong D. E.H., Hartono J. L., Lee J. W.J. Oral Microbiome of Crohn’s Disease Patients With and Without Oral Manifestations. J Crohns Colitis. 2022 Nov 1;16(10):1628-1636. doi: 10.1093/ecco-jcc/jjac063.Hu S., Mok J., Gowans M., Ong D. E.H., Hartono J. L., Lee J. W.J. Oral Microbiome of Crohn’s Disease Patients With and Without Oral Manifestations. J Crohns Colitis. 2022 Nov 1;16(10):1628-1636. doi: 10.1093/ecco-jcc/jjac063.Abdelbary M.M.H., Hatting M., Bott A., Dahlhausen A., Keller D., Trautwein C., Conrads G. The oral-gut axis: Salivary and fecal microbiome dysbiosis in patients with inflammatory bowel disease. Front Cell Infect Microbiol. 2022 Oct 7;12:1010853. doi: 10.3389/fcimb.2022.1010853.Abdelbary M.M.H., Hatting M., Bott A., Dahlhausen A., Keller D., Trautwein C., Conrads G. The oral-gut axis: Salivary and fecal microbiome dysbiosis in patients with inflammatory bowel disease. Front Cell Infect Microbiol. 2022 Oct 7;12:1010853. doi: 10.3389/fcimb.2022.1010853.Brito F., Zaltman C., Carvalho A. T., Fischer R. G., Persson R., Gustafsson A., Figueredo C. M. Subgingival microflora in inflammatory bowel disease patients with untreated periodontitis. Eur J Gastroenterol Hepatol. 2013 Feb;25(2):239-45. doi: 10.1097/MEG.0b013e32835a2b70.Brito F., Zaltman C., Carvalho A. T., Fischer R. G., Persson R., Gustafsson A., Figueredo C. M. Subgingival microflora in inflammatory bowel disease patients with untreated periodontitis. Eur J Gastroenterol Hepatol. 2013 Feb;25(2):239-45. doi: 10.1097/MEG.0b013e32835a2b70.Kelsen J., Bittinger K., Pauly-Hubbard H., Posivak L., Grunberg S., Baldassano R., Lewis J. D., Wu G. D., Bushman F. D. Alterations of the Subgingival Microbiota in Pediatric Crohn’s Disease Studied Longitudinally in Discovery and Validation Cohorts. Inflamm Bowel Dis. 2015 Dec;21(12):2797-805. doi: 10.1097/MIB.0000000000000557.Kelsen J., Bittinger K., Pauly-Hubbard H., Posivak L., Grunberg S., Baldassano R., Lewis J. D., Wu G. D., Bushman F. D. Alterations of the Subgingival Microbiota in Pediatric Crohn’s Disease Studied Longitudinally in Discovery and Validation Cohorts. Inflamm Bowel Dis. 2015 Dec;21(12):2797-805. doi: 10.1097/MIB.0000000000000557.Elmaghrawy K., Fleming P., Fitzgerald K., Cooper S., Dominik A., Hussey S., Moran G. P. The Oral Microbiome in Treatment-Naïve Paediatric IBD Patients Exhibits Dysbiosis Related to Disease Severity that Resolves Following Therapy. J Crohns Colitis. 2023 Apr 19;17(4):553-564. doi: 10.1093/ecco-jcc/jjac155.Elmaghrawy K., Fleming P., Fitzgerald K., Cooper S., Dominik A., Hussey S., Moran G. P. The Oral Microbiome in Treatment-Naïve Paediatric IBD Patients Exhibits Dysbiosis Related to Disease Severity that Resolves Following Therapy. J Crohns Colitis. 2023 Apr 19;17(4):553-564. doi: 10.1093/ecco-jcc/jjac155.Davenport M., Poles J., Leung J. M., Wolff M. J., Abidi W. M., Ullman T., Mayer L., Cho I., Loke P. Metabolic alterations to the mucosal microbiota in inflammatory bowel disease. Inflamm Bowel Dis. 2014 Apr;20(4):723-31. doi: 10.1097/MIB.0000000000000011.Davenport M., Poles J., Leung J. M., Wolff M. J., Abidi W. M., Ullman T., Mayer L., Cho I., Loke P. Metabolic alterations to the mucosal microbiota in inflammatory bowel disease. Inflamm Bowel Dis. 2014 Apr;20(4):723-31. doi: 10.1097/MIB.0000000000000011.Chen L., Wang W., Zhou R., Ng S. C., Li J., Huang M., Zhou F., Wang X., Shen B., A Kamm M., Wu K., Xia B. Characteristics of fecal and mucosa-associated microbiota in Chinese patients with inflammatory bowel disease. Medicine (Baltimore). 2014 Aug;93(8): e51. doi: 10.1097/MD.0000000000000051.Chen L., Wang W., Zhou R., Ng S. C., Li J., Huang M., Zhou F., Wang X., Shen B., A Kamm M., Wu K., Xia B. Characteristics of fecal and mucosa-associated microbiota in Chinese patients with inflammatory bowel disease. Medicine (Baltimore). 2014 Aug;93(8): e51. doi: 10.1097/MD.0000000000000051.Santoru M.L., Piras C., Murgia A., Palmas V. et al. Cross sectional evaluation of the gut-microbiome metabolome axis in an Italian cohort of IBD patients. Sci Rep. 2017 Aug 25;7(1):9523. doi: 10.1038/s41598-017-10034-5.Santoru M.L., Piras C., Murgia A., Palmas V. et al. Cross sectional evaluation of the gut-microbiome metabolome axis in an Italian cohort of IBD patients. Sci Rep. 2017 Aug 25;7(1):9523. doi: 10.1038/s41598-017-10034-5.Imhann F., Vich Vila A., Bonder M. J., Fu J. et al.Interplay of host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory bowel disease. Gut. 2018 Jan;67(1):108-119. doi: 10.1136/gutjnl-2016-312135.Imhann F., Vich Vila A., Bonder M. J., Fu J. et al.Interplay of host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory bowel disease. Gut. 2018 Jan;67(1):108-119. doi: 10.1136/gutjnl-2016-312135.Zakrzewski M., Simms L. A., Brown A., Appleyard M., Irwin J., Waddell N., Radford-Smith G.L. IL23R-Protective Coding Variant Promotes Beneficial Bacteria and Diversity in the Ileal Microbiome in Healthy Individuals Without Inflammatory Bowel Disease. J Crohns Colitis. 2019 Mar 30;13(4):451-461. doi: 10.1093/ecco-jcc/jjy188.Zakrzewski M., Simms L. A., Brown A., Appleyard M., Irwin J., Waddell N., Radford-Smith G.L. IL23R-Protective Coding Variant Promotes Beneficial Bacteria and Diversity in the Ileal Microbiome in Healthy Individuals Without Inflammatory Bowel Disease. J Crohns Colitis. 2019 Mar 30;13(4):451-461. doi: 10.1093/ecco-jcc/jjy188.Altomare A., Putignani L., Del Chierico F., Cocca S. et al. Gut mucosal-associated microbiota better discloses inflammatory bowel disease differential patterns than faecal microbiota. Dig Liver Dis. 2019 May;51(5):648-656. doi: 10.1016/j.dld.2018.11.021.Altomare A., Putignani L., Del Chierico F., Cocca S. et al. Gut mucosal-associated microbiota better discloses inflammatory bowel disease differential patterns than faecal microbiota. Dig Liver Dis. 2019 May;51(5):648-656. doi: 10.1016/j.dld.2018.11.021.Franzosa E.A., Sirota-Madi A., Avila-Pacheco J., Fornelos N. et al. Gut microbiome structure and metabolic activity in inflammatory bowel disease. Nat Microbiol. 2019 Feb;4(2):293-305. doi: 10.1038/s41564-018-0306-4.Franzosa E.A., Sirota-Madi A., Avila-Pacheco J., Fornelos N. et al. Gut microbiome structure and metabolic activity in inflammatory bowel disease. Nat Microbiol. 2019 Feb;4(2):293-305. doi: 10.1038/s41564-018-0306-4.Li E., Zhang Y., Tian X., Wang X. et al. Influence of Crohn’s disease related polymorphisms in innate immune function on ileal microbiome. PLoS One. 2019 Feb 28;14(2): e0213108. doi: 10.1371/journal.pone.0213108.Li E., Zhang Y., Tian X., Wang X. et al. Influence of Crohn’s disease related polymorphisms in innate immune function on ileal microbiome. PLoS One. 2019 Feb 28;14(2): e0213108. doi: 10.1371/journal.pone.0213108.Yilmaz B., Juillerat P., Øyås O., Ramon C., Bravo F. D., Franc Y., Fournier N., Michetti P., Mueller C., Geuking M., Pittet V. E.H., Maillard M. H., Rogler G.; Swiss IBD Cohort Investigators; Wiest R, Stelling J, Macpherson AJ. Microbial network disturbances in relapsing refractory Crohn’s disease. Nat Med. 2019 Feb;25(2):323-336. doi: 10.1038/s41591-018-0308-z.Yilmaz B., Juillerat P., Øyås O., Ramon C., Bravo F. D., Franc Y., Fournier N., Michetti P., Mueller C., Geuking M., Pittet V. E.H., Maillard M. H., Rogler G.; Swiss IBD Cohort Investigators; Wiest R, Stelling J, Macpherson AJ. Microbial network disturbances in relapsing refractory Crohn’s disease. Nat Med. 2019 Feb;25(2):323-336. doi: 10.1038/s41591-018-0308-z.Magro D.O., Santos A., Guadagnini D. et al. Remission in Crohn’s disease is accompanied by alterations in the gut microbiota and mucins production. Sci Rep. 2019 Sep 13;9(1):13263. doi: 10.1038/s41598-019-49893-5.Magro D.O., Santos A., Guadagnini D. et al. Remission in Crohn’s disease is accompanied by alterations in the gut microbiota and mucins production. Sci Rep. 2019 Sep 13;9(1):13263. doi: 10.1038/s41598-019-49893-5.Zhang Y.L., Cai L. T., Qi J. Y. et al. Gut microbiota contributes to the distinction between two traditional Chinese medicine syndromes of ulcerative colitis. World J Gastroenterol. 2019 Jul 7;25(25):3242-3255. doi: 10.3748/wjg.v25.i25.3242.Zhang Y.L., Cai L. T., Qi J. Y. et al. Gut microbiota contributes to the distinction between two traditional Chinese medicine syndromes of ulcerative colitis. World J Gastroenterol. 2019 Jul 7;25(25):3242-3255. doi: 10.3748/wjg.v25.i25.3242.Alam M.T., Amos G. C.A., Murphy A. R.J., Murch S., Wellington E. M.H., Arasaradnam R. P. Microbial imbalance in inflammatory bowel disease patients at different taxonomic levels. Gut Pathog. 2020 Jan 4;12:1. doi: 10.1186/s13099-019-0341-6.Alam M.T., Amos G. C.A., Murphy A. R.J., Murch S., Wellington E. M.H., Arasaradnam R. P. Microbial imbalance in inflammatory bowel disease patients at different taxonomic levels. Gut Pathog. 2020 Jan 4;12:1. doi: 10.1186/s13099-019-0341-6.Ryan F.J., Ahern A. M., Fitzgerald R. S. et al. Colonic microbiota is associated with inflammation and host epigenomic alterations in inflammatory bowel disease. Nat Commun. 2020 Mar 23;11(1):1512. doi: 10.1038/s41467-020-15342-5.Ryan F.J., Ahern A. M., Fitzgerald R. S. et al. Colonic microbiota is associated with inflammation and host epigenomic alterations in inflammatory bowel disease. Nat Commun. 2020 Mar 23;11(1):1512. doi: 10.1038/s41467-020-15342-5.Olaisen M., Flatberg A., Granlund A. V.B., Røyset E. S., Martinsen T. C., Sandvik A. K., Fossmark R. Bacterial Mucosa-associated Microbiome in Inflamed and Proximal Noninflamed Ileum of Patients With Crohn’s Disease. Inflamm Bowel Dis. 2021 Jan 1;27(1):12-24. doi: 10.1093/ibd/izaa107.Olaisen M., Flatberg A., Granlund A. V.B., Røyset E. S., Martinsen T. C., Sandvik A. K., Fossmark R. Bacterial Mucosa-associated Microbiome in Inflamed and Proximal Noninflamed Ileum of Patients With Crohn’s Disease. Inflamm Bowel Dis. 2021 Jan 1;27(1):12-24. doi: 10.1093/ibd/izaa107.Shahir N.M., Wang J. R., Wolber E. A. et al. Crohn’s Disease Differentially Affects Region-Specific Composition and Aerotolerance Profiles of Mucosally Adherent Bacteria. Inflamm Bowel Dis. 2020 Nov 19;26(12):1843-1855. doi: 10.1093/ibd/izaa103.Shahir N.M., Wang J. R., Wolber E. A. et al. Crohn’s Disease Differentially Affects Region-Specific Composition and Aerotolerance Profiles of Mucosally Adherent Bacteria. Inflamm Bowel Dis. 2020 Nov 19;26(12):1843-1855. doi: 10.1093/ibd/izaa103.Clooney A.G., Eckenberger J., Laserna-Mendieta E. et al. Ranking microbiome variance in inflammatory bowel disease: a large longitudinal intercontinental study. Gut. 2021 Mar;70(3):499-510. doi: 10.1136/gutjnl-2020-321106.Clooney A.G., Eckenberger J., Laserna-Mendieta E. et al. Ranking microbiome variance in inflammatory bowel disease: a large longitudinal intercontinental study. Gut. 2021 Mar;70(3):499-510. doi: 10.1136/gutjnl-2020-321106.Park Y.M., Ha E., Gu K. N., Shin G. Y., Lee C. K., Kim K., Kim H. J. Host Genetic and Gut Microbial Signatures in Familial Inflammatory Bowel Disease. Clin Transl Gastroenterol. 2020 Jul;11(7): e00213. doi: 10.14309/ctg.0000000000000213.Park Y.M., Ha E., Gu K. N., Shin G. Y., Lee C. K., Kim K., Kim H. J. Host Genetic and Gut Microbial Signatures in Familial Inflammatory Bowel Disease. Clin Transl Gastroenterol. 2020 Jul;11(7): e00213. doi: 10.14309/ctg.0000000000000213.Lo Sasso G., Khachatryan L., Kondylis A. et al. Inflammatory Bowel Disease-Associated Changes in the Gut: Focus on Kazan Patients. Inflamm Bowel Dis. 2021 Feb 16;27(3):418-433. doi: 10.1093/ibd/izaa188.Lo Sasso G., Khachatryan L., Kondylis A. et al. Inflammatory Bowel Disease-Associated Changes in the Gut: Focus on Kazan Patients. Inflamm Bowel Dis. 2021 Feb 16;27(3):418-433. doi: 10.1093/ibd/izaa188.

The authors declare that there are no conflicts of interest present.